Reuters logo
BRIEF-Orexigen Therapeutics reports Q4 loss per share $1.69
March 28, 2017 / 8:32 PM / 8 months ago

BRIEF-Orexigen Therapeutics reports Q4 loss per share $1.69

March 28 (Reuters) - Orexigen Therapeutics Inc -

* Orexigen Therapeutics reports financial results for the fourth quarter and year ended December 31, 2016

* Q4 loss per share $1.69

* Q4 revenue $13.9 million versus $4.9 million

* According to IMS Health, 140,755 total prescriptions of contrave were filled in q4 of 2016 versus 185,944 total prescriptions filled in q4 of 2015 Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below